Methocarbamol (Robaxin)

Methocarbamol is a prescription skeletal muscle relaxant that depresses the central nervous system to relieve acute painful musculoskeletal conditions. It comes as 500mg and 750mg tablets for use alongside rest and physical therapy.

• Dose: 500mg initial 6g/day; 750mg initial 6g/day; maintenance 4g/day
• Status: Prescription required, skeletal muscle relaxant, CNS depressant
• Primary use: Acute painful musculoskeletal conditions, adjunct to rest and PT
• Half-life: 1 to 2 hours in healthy adults, onset 30 minutes

What Is Methocarbamol

Methocarbamol is a carbamate derivative of guaifenesin classified as a skeletal muscle relaxant. The FDA approved it as an adjunct to rest, physical therapy and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. It is available as 500mg and 750mg tablets for oral administration. The brand name is Robaxin.

Methocarbamol is a white powder sparingly soluble in water. Its chemical formula is C11H15NO5 with a molecular weight of 241.24. The 500mg tablets are round, scored, white to off-white and debossed with identification markings. The 750mg tablets are capsule-shaped, white to off-white and debossed with “S226”. Store at controlled room temperature between 20 degrees Celsius and 25 degrees Celsius.

How Methocarbamol Works

The precise mechanism of action of methocarbamol in humans has not been established. It may be related to general central nervous system depression. Methocarbamol does not directly relax tense skeletal muscles. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.

Key mechanisms:

• General CNS depression: Sedative properties may interrupt the pain-spasm-pain cycle.
• No direct muscle action: Does not affect striated muscle contractility or motor nerve fibers.
• Adjunctive therapy: Works alongside rest and physical therapy, not as a standalone treatment.
• Short half-life: 1 to 2 hours in healthy adults, requiring frequent dosing.

Conditions Treated by Methocarbamol

The FDA approved methocarbamol for one primary indication. It is used as an adjunct to rest, physical therapy and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. Methocarbamol is not indicated for chronic muscle spasticity, neurological conditions or as a standalone pain reliever.

• Acute painful musculoskeletal conditions: Muscle strains, sprains and acute back pain. Used alongside rest and physical therapy to reduce discomfort.
• Not indicated for: Chronic muscle spasticity, cerebral palsy, multiple sclerosis or spinal cord injury. Other agents are preferred for these conditions.
• Not a standalone analgesic: Methocarbamol does not treat the underlying cause of pain. It is an adjunct to comprehensive musculoskeletal care.

Methocarbamol Dosage and Strengths

Methocarbamol is available in two tablet strengths for oral administration. Dosing varies by tablet strength and treatment phase. The initial phase uses higher doses for 48 to 72 hours. The maintenance phase reduces the dose once acute symptoms improve significantly.

Available Forms

• 500mg tablets: Round, scored, white to off-white. Debossed with manufacturer markings.
• 750mg tablets: Capsule-shaped, white to off-white. Debossed with “S226”.

Standard Adult Dosing

For 500mg tablets, the initial dosage is 3 tablets four times daily. The maintenance dosage is 2 tablets four times daily. Six grams per day are recommended for the first 48 to 72 hours of treatment. For severe conditions, 8 grams per day may be administered during this initial period.

For 750mg tablets, the initial dosage is 2 tablets four times daily. The maintenance dosage is 1 tablet every 4 hours or 2 tablets three times daily. Thereafter, the dosage can usually be reduced to 4 grams per day.

Take methocarbamol with or without food as directed by your doctor. Do not increase your dose or use it more often or for longer than prescribed. Your condition will not improve faster and your risk of side effects will increase.

Missed Dose Instructions

Take the missed dose as soon as you remember. Skip it if it is near the time of the next dose. Do not double the dose to catch up. Doubling increases CNS depression, dizziness and sedation risk. Resume your normal schedule at the next dose.

Side Effects

Adverse reactions reported coincident with methocarbamol administration include CNS effects, cardiovascular events and hypersensitivity reactions. Some events may be due to overly rapid intravenous injection. Most side effects are mild and resolve after dose reduction or discontinuation of methocarbamol therapy.

Common Side Effects

Adverse reactions reported in clinical trials and post-marketing surveillance include:

• Drowsiness and sedation
• Dizziness or lightheadedness
• Headache
• Nausea and vomiting
• Blurred vision
• Insomnia
• Confusion
• Metallic taste
• Nasal congestion
• Pruritus and rash

Serious Side Effects

Stop taking methocarbamol and contact a doctor immediately if you experience:

• Anaphylactic reaction or angioneurotic edema: difficulty breathing, facial swelling, hives, rapid heartbeat. Seek emergency care immediately.
• Syncope or severe hypotension: fainting, extreme dizziness, especially after standing. Bradycardia and flushing have been reported.
• Seizures: convulsions or loss of consciousness. The onset of seizures during intravenous administration has been reported in patients with seizure disorders.
• Jaundice or cholestatic jaundice: yellowing skin, dark urine, severe fatigue, right upper quadrant pain. Stop methocarbamol immediately if liver dysfunction develops.
• Leukopenia: unusual bruising, bleeding, or frequent infections. Monitor blood counts if symptoms develop.
• Thrombophlebitis: pain, redness or swelling at injection sites. This applies to the injectable form.

Who Should Not Take Methocarbamol

Do not take methocarbamol if you have hypersensitivity to methocarbamol or any tablet component. Avoid methocarbamol if you have a known seizure disorder unless specifically directed by a neurologist. The injectable form is contraindicated in patients with known or suspected renal pathology due to polyethylene glycol 300 content.

Methocarbamol should not be used in women who are or may become pregnant, particularly during early pregnancy, unless the potential benefits outweigh the possible hazards. There have been reports of fetal and congenital abnormalities following in utero exposure.

Warnings and Precautions

Methocarbamol may cause general CNS depressant effects. Patients should be cautioned about combined effects with alcohol and other CNS depressants including benzodiazepines, opioids and sedating antihistamines. Methocarbamol may impair mental and physical abilities required for operating machinery or driving a vehicle.

CNS Depression and Sedation

Methocarbamol causes drowsiness and dizziness. These effects may impair the ability to operate motor vehicles or machinery. Patients should be cautioned about operating automobiles until they are reasonably certain that methocarbamol therapy does not adversely affect their ability. Avoid alcohol and other CNS depressants during treatment.

Seizure Disorders

Caution is advised when using the injectable form in patients with suspected or known seizure disorders. The onset of convulsive seizures during intravenous administration has been reported. The psychic trauma of the procedure may have been a contributing factor. Although success in terminating epileptiform seizures has been reported, administration to patients with epilepsy is not recommended.

Use in Activities Requiring Mental Alertness

Methocarbamol may impair mental and physical abilities required for performance of hazardous tasks. Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that methocarbamol therapy does not adversely affect their ability to engage in such activities.

Pregnancy and Fetal Risk

Safe use of methocarbamol has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure. Methocarbamol should not be used in women who are or may become pregnant, particularly during early pregnancy, unless the potential benefits outweigh the possible hazards.

Drug Interactions

Methocarbamol interacts with CNS depressants and anticholinesterase agents. Always provide your doctor with a complete medication list before starting methocarbamol. The sedative effects of methocarbamol are additive with other central nervous system depressants including opioids, benzodiazepines and other sedating antihistamines.

• Alcohol and other CNS depressants: Additive sedation, dizziness and respiratory depression. Avoid concurrent use with benzodiazepines, opioids, barbiturates and sedating antihistamines.
• Pyridostigmine bromide and other anticholinesterase agents: Methocarbamol may inhibit the effect of pyridostigmine. Use caution in patients with myasthenia gravis receiving anticholinesterase therapy.
• CNS-active medications: Antidepressants, antipsychotics and sleep aids may compound sedation. Monitor for excessive drowsiness.

Drug and Laboratory Test Interactions

Methocarbamol may cause color interference in certain screening tests for 5-hydroxyindoleacetic acid using nitrosonaphthol reagent and in screening tests for urinary vanillylmandelic acid using the Gitlow method. Inform laboratory personnel that you are taking methocarbamol before urine testing.

Methocarbamol and Pregnancy

Methocarbamol is classified as Pregnancy Category C. Animal reproduction studies have not been conducted. It is not known whether methocarbamol can cause fetal harm when administered to a pregnant woman. There have been reports of fetal and congenital abnormalities following in utero exposure.

Methocarbamol should not be used in women who are or may become pregnant, particularly during early pregnancy, unless the potential benefits outweigh the possible hazards. It is not known whether methocarbamol or its metabolites are excreted in human milk. Caution should be exercised when administering methocarbamol to a nursing woman.

Overdose Information

Overdose of methocarbamol is frequently in conjunction with alcohol or other CNS depressants. Symptoms include nausea, drowsiness, blurred vision, hypotension, seizures and coma. In post-marketing experience, deaths have been reported with overdose of methocarbamol alone or in the presence of other CNS depressants, alcohol or psychotropic drugs.

Management of overdose includes symptomatic and supportive treatment. Maintain an adequate airway. Monitor urinary output and vital signs. Administer intravenous fluids if necessary. The usefulness of hemodialysis in managing overdose is unknown. Contact poison control at 1-800-222-1222. Seek emergency care for severe symptoms.

Storage and Handling

Store methocarbamol tablets at controlled room temperature between 20 degrees Celsius and 25 degrees Celsius. Excursions permitted to 15 to 30 degrees Celsius. Keep in a dry place in a tight container. Keep out of reach of children. Discard expired products. Do not use if the seal is broken. Protect from moisture and light.

Frequently Asked Questions

Sources and References

• U.S. Food and Drug Administration – Methocarbamol Tablets Prescribing Information, NDA 011011
• DailyMed – Methocarbamol Tablets USP 500mg and 750mg Drug Label, National Library of Medicine, Revised 09/2025
• PubMed – Sibrack J et al. Methocarbamol. StatPearls. NCBI Bookshelf, 2024
• PubMed – Methocarbamol clinical pharmacokinetics and special populations. FDA Pharmacology Review